Pinterest Stock Surges After Strong Q1 2026 Earnings Beat Expectations 
Ford Q1 Earnings Beat Expectations, Stock Surges on Strong Guidance 
Apple Explores Intel and Samsung Partnerships to Diversify Chip Supply Chain 
Volvo Car Sales Drop 10% in Early 2026 Despite Growth in Electric Vehicles 
Spirit Airlines Shuts Down Flights, Issues Refunds After Financial Collapse 
Berkshire Hathaway Meeting Sees Shift as Greg Abel Steps Into Leadership Spotlight 
Anthropic’s $1.5B AI Venture with Wall Street Firms Targets Private Equity Market 
Intel Emerges as Key Contender in Apple’s Chip Manufacturing Strategy Shift 
Standard Chartered Q1 Profit Hits Record on Wealth and Investment Banking Growth 
Meta Plans $13B AI Data Center Financing in Texas Amid Surging Big Tech Investment 
Hugo Boss Beats Q1 Profit Expectations Despite Market Headwinds 
GameStop Eyes eBay Acquisition as Stock Prices Surge After Hours 
Qualcomm Stock Surges Despite Weak Guidance After Q2 2026 Earnings Beat 
Regis Resources and Vault Minerals to Merge in $10.7B Gold Deal 
U.S. Cybersecurity Pushes Faster Patch Deadlines Amid Rising AI-Driven Threats 
LONDON and CARLSBAD, Calif., May 08, 2018 -- GW Pharmaceuticals plc (NASDAQ:GWPH) (GW, the Company or the Group), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced that GW management will present at the Bank of America Merrill Lynch 2018 Health Care Conference on Tuesday, May 15, 2018 at 1:00 p.m. PT in Las Vegas, Nevada.
A live audio webcast of the presentation will be available through GW’s corporate website in the investor relations section from the investor’s calendar of events page at www.gwpharm.com. A replay will be available soon after the live presentation.
About GW Pharmaceuticals plc and Greenwich Biosciences
Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. GW, along with its U.S. subsidiary Greenwich Biosciences, is advancing an orphan drug program in the field of childhood-onset epilepsy with a focus on Epidiolex (cannabidiol), for which GW has submitted regulatory applications in the U.S. and Europe for the adjunctive treatment of Lennox-Gastaut syndrome and Dravet syndrome. The Company continues to evaluate Epidiolex in additional rare epilepsy conditions and currently has ongoing clinical trials in Tuberous Sclerosis Complex and Infantile Spasms. GW commercialized the world’s first plant-derived cannabinoid prescription drug, Sativex® (nabiximols), which is approved for the treatment of spasticity due to multiple sclerosis in numerous countries outside the United States and for which the company is now planning a US Phase 3 trial. The Company has a deep pipeline of additional cannabinoid product candidates which includes compounds in Phase 1 and 2 trials for epilepsy, glioblastoma, and schizophrenia. For further information, please visit www.gwpharm.com.
Enquiries:
| GW Pharmaceuticals plc | |
| Stephen Schultz, VP Investor Relations (U.S.) | 917 280 2424 / 401 500 6570 |
